On August 7th, 2020, the Food and Drug Administration (FDA) approved the Guardant 360 CDx for comprehensive biomarker testing for patients with any solid tumor. The FDA based their approval on data from the clinical trials FLAURA and AURA3 [...]
GO2 for Lung Cancer recognizes Professor Swanton for genetic research transforming lung cancer treatment San Carlos, CA and Washington, D.C., July 23, 2020 – GO2 for Lung Cancer (GO2 for Lung Cancer) will present Charles Swanton, M.D., Ph.D., FRCP, [...]
WASHINGTON, June 23, 2020 /PRNewswire/ -- The Lung Cancer Registry has launched a landmark new survey on the impact of lung treatments on women's sexual health. The aim is to explore the magnitude of the problem and give researchers and clinicians new insights [...]
A historic milestone was reached today with the exciting announcement that the Department of Veterans Affairs (VA) and GO2 for Lung Cancer (GO2 for Lung Cancer) have established a formal partnership to advance lifesaving screening and care for our [...]
SAN CARLOS, Calif. and WASHINGTON, May 13, 2020 /PRNewswire/ -- GO2 for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global [...]
On March 27, 2020, the Food and Drug Administration (FDA) approved Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin as first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA based their [...]
SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung [...]
GO2 for Lung Cancer points to targeted treatments and early screenings SAN CARLOS, Calif. and WASHINGTON, Jan. 8, 2020 /PRNewswire/ -- Today's report concerning improvements in cancer mortality is welcomed news. The recently released Cancer Statistics 2020 report shows that the decline in lung cancer deaths [...]
SAN CARLOS, Calif. and WASHINGTON DC, December 12, 2019 – The Lung Cancer Registry has launched new surveys to do an even better job of capturing important moments in a patient’s lung cancer journey. These new surveys include questions [...]
On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no [...]